89 related articles for article (PubMed ID: 27524244)
1. Genome-scale functional analysis of the human genes modulating p53 activity by regulating MDM2 expression in a p53-independent manner.
Kim DM; Choi SH; Yeom YI; Min SH; Kim IC
Biochem Biophys Res Commun; 2016 Sep; 478(2):976-81. PubMed ID: 27524244
[TBL] [Abstract][Full Text] [Related]
2. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
4. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells.
Kao CL; Hsu HS; Chen HW; Cheng TH
Cancer Lett; 2009 Dec; 286(2):250-9. PubMed ID: 19560264
[TBL] [Abstract][Full Text] [Related]
6. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
7. Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.
Ralhan R; Sandhya A; Meera M; Bohdan W; Nootan SK
Am J Pathol; 2000 Aug; 157(2):587-96. PubMed ID: 10934161
[TBL] [Abstract][Full Text] [Related]
8. Defects in transcription coupled repair interfere with expression of p90(MDM2) in response to ultraviolet light.
Michalowski J; Seavey SE; Mendrysa SM; Perry ME
Oncogene; 2001 Sep; 20(41):5856-64. PubMed ID: 11593391
[TBL] [Abstract][Full Text] [Related]
9. Identification of functional DNA variants in the constitutive promoter region of MDM2.
Lalonde ME; Ouimet M; Larivière M; Kritikou EA; Sinnett D
Hum Genomics; 2012 Sep; 6(1):15. PubMed ID: 23244604
[TBL] [Abstract][Full Text] [Related]
10. E2F1 inhibits MDM2 expression in a p53-dependent manner.
Tian X; Chen Y; Hu W; Wu M
Cell Signal; 2011 Jan; 23(1):193-200. PubMed ID: 20837136
[TBL] [Abstract][Full Text] [Related]
11. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
12. A Novel Interaction between TFII-I and Mdm2 with a Negative Effect on TFII-I Transcriptional Activity.
Cetkovská K; Šustová H; Kosztyu P; Uldrijan S
PLoS One; 2015; 10(12):e0144753. PubMed ID: 26656605
[TBL] [Abstract][Full Text] [Related]
13. Expression screening using a Medaka cDNA library identifies evolutionarily conserved regulators of the p53/Mdm2 pathway.
Zhang P; Kratz AS; Salama M; Elabd S; Heinrich T; Wittbrodt J; Blattner C; Davidson G
BMC Biotechnol; 2015 Oct; 15():92. PubMed ID: 26450685
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene.
Liang H; Lunec J
Gene; 2005 Nov; 361():112-8. PubMed ID: 16202543
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
16. Study of Arsenic Sulfide in Solid Tumor Cells Reveals Regulation of Nuclear Factors of Activated T-cells by PML and p53.
Ding W; Tong Y; Zhang X; Pan M; Chen S
Sci Rep; 2016 Jan; 6():19793. PubMed ID: 26795951
[TBL] [Abstract][Full Text] [Related]
17. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
18. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
19. BCL11B tumor suppressor inhibits HDM2 expression in a p53-dependent manner.
Obata M; Kominami R; Mishima Y
Cell Signal; 2012 May; 24(5):1047-52. PubMed ID: 22245141
[TBL] [Abstract][Full Text] [Related]
20. Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2.
Lee SJ; Lim CJ; Min JK; Lee JK; Kim YM; Lee JY; Won MH; Kwon YG
Cell Death Differ; 2007 Jun; 14(6):1106-16. PubMed ID: 17318220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
